Official AMFI data
Arthkar

Listed equity

Alivus Life Sciences

NSE: ALIVUSBSE: 543322M-cap ₹14.2K Cr8 mutual funds hold this
1148.302.55(-0.22%)

EOD close · 3 Jul 2026

mid rallyneutral -9

Above 50- and 200-day MAs with +17.2% over 3 months — established uptrend.

52W low ₹830.0052W high ₹1193.30

Now at 88% of its 52-week range

Long-term returns

1Y
+12.3%
3Y
+101.9%

Phase indicator

mid rally-3.8% from 52w high

Above 50- and 200-day MAs with +17.2% over 3 months — established uptrend.

1M
+11.7%
3M
+17.2%
1Y
+12.3%

Delivery conviction

neutralscore -9
Delivery vs 20-day avg0.75x

Lifetime story

Alivus Life Sciences is up 211.2% from its lifetime low of 369.00 on 22 Feb 2023. ₹10,000 invested then would be worth 31,119 today (40.2% CAGR over 3.4 years). Lifetime high of 1335.00 was set on 16 Sept 2024 (currently -14.0% below).

Fundamentals

Standalone vs consolidated — most retail products show only one. Consolidated includes subsidiary contribution.

49% cheaper than industry(Industry P/E 49.5)
StandaloneConsolidated
P/E (TTM)subs material25.160.00
P/B4.27
Price / Cash flowsubs material22.190.00
Dividend yield0.43%0.43%
Book value / share271.48 ₹
EPS (TTM)subs material45.99 ₹0.00 ₹
Market cap
₹14.2K Cr
52W high
₹1193.30
2 Jul 2026
52W low
₹830.00
22 Jan 2026

Returns ladder

1W
+4.5%
1M
+11.7%
3M
+17.2%
6M
+26.7%
YTD
+26.1%
1Y
+12.3%
3Y
+101.9%
5Y
10Y
Since listing
+54.6%